All In Biotech

Drug Trial Radar · NCT05983445

Safety & Efffficacy of Genakumab in Patients With Frequent Flares

Safety & Efficacy of Genakumab in Patients With Frequent Flares

Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 313 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

313

Actual

Start

Jan 11, 2023

Primary completion

Apr 3, 2024

Study completion Apr 3, 2024

Sponsor

Sponsor type
Industry
First posted
Aug 9, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy and safety of Genakumab Injection in patients with Gouty Arthritis (GA).

Conditions

  • Acute Gout Arthritis

Interventions

  • genakumabDrug

    200mg s.c.

  • placebo for DiprospanDrug

    i.m.

  • placebo for genakumabDrug

    s.c.

  • DiprospanDrug

    7mg i.m.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The change in the gout pain intensity in the target joint measured by VASTime frame: 72 hours post-dose
  2. Time to first new flareTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fudan University Affiliated Huashan Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.